» Articles » PMID: 24022395

Offering Fragile X Syndrome Carrier Screening: a Prospective Mixed-methods Observational Study Comparing Carrier Screening of Pregnant and Non-pregnant Women in the General Population

Overview
Journal BMJ Open
Specialty General Medicine
Date 2013 Sep 12
PMID 24022395
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Fragile X syndrome (FXS) is the leading cause of inherited intellectual and developmental disability. Policy development relating to carrier screening programmes for FXS requires input from large studies examining not only test uptake but also psychosocial aspects. This study will compare carrier screening in pregnant and non-pregnant populations, examining informed decision-making, psychosocial issues and health economics.

Methods And Analysis: Pregnant and non-pregnant women are being recruited from general practices and obstetric services. Women receive study information either in person or through clinic mail outs. Women are provided pretest counselling by a genetic counsellor and make a decision about testing in their own time. Data are being collected from two questionnaires: one completed at the time of making the decision about testing and the second 1 month later. Additional data are gathered through qualitative interviews conducted at several time points with a subset of participating women, including all women with a positive test result, and with staff from recruiting clinics. A minimum sample size of 500 women/group has been calculated to give us 88% power to detect a 10% difference in test uptake and 87% power to detect a 10% difference in informed choice between the pregnant and non-pregnant groups. Questionnaire data will be analysed using descriptive statistics and multivariate logistic regression models. Interview data will be thematically analysed. Willingness-to-pay and cost effectiveness analyses will also be performed. Recruitment started in July 2009 and data collection will be completed by December 2013.

Ethics And Dissemination: Ethics approval has been granted by the Universities of Melbourne and Western Australia and by recruiting clinics, where required. Results will be reported in peer-reviewed publications, conference presentations and through a website http://www.fragilexscreening.net.au. The results of this study will make a significant contribution to discussions about the wider introduction of population carrier screening for FXS.

Citing Articles

Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on Premutation.

Tassone F, Protic D, Allen E, Archibald A, Baud A, Brown T Cells. 2023; 12(18).

PMID: 37759552 PMC: 10529056. DOI: 10.3390/cells12182330.


The Australian Reproductive Genetic Carrier Screening Project (Mackenzie's Mission): Design and Implementation.

Archibald A, McClaren B, Caruana J, Tutty E, King E, Halliday J J Pers Med. 2022; 12(11).

PMID: 36579509 PMC: 9698511. DOI: 10.3390/jpm12111781.


Understanding the Molecular Basis of Fragile X Syndrome Using Differentiated Mesenchymal Stem Cells.

Fazeli Z, Ghaderian S, Najmabadi H, Omrani M Iran J Child Neurol. 2022; 16(1):85-95.

PMID: 35222660 PMC: 8753000. DOI: 10.22037/ijcn.v15i4.22070.


Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening.

Clarke E, Schneider J, Lynch F, Kauffman T, Leo M, Rosales A PLoS One. 2018; 13(7):e0200139.

PMID: 30020962 PMC: 6051630. DOI: 10.1371/journal.pone.0200139.


Informed decision making and psychosocial outcomes in pregnant and nonpregnant women offered population fragile X carrier screening.

Metcalfe S, Martyn M, Ames A, Anderson V, Archibald A, Carter R Genet Med. 2017; 19(12):1346-1355.

PMID: 28661491 DOI: 10.1038/gim.2017.67.


References
1.
Berry-Kravis E, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K . Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012; 4(152):152ra127. DOI: 10.1126/scitranslmed.3004214. View

2.
Tassone F, Pan R, Amiri K, Taylor A, Hagerman P . A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008; 10(1):43-9. PMC: 2175542. DOI: 10.2353/jmoldx.2008.070073. View

3.
Archibald A, Jaques A, Wake S, Collins V, Cohen J, Metcalfe S . "It's something I need to consider": decisions about carrier screening for fragile X syndrome in a population of non-pregnant women. Am J Med Genet A. 2009; 149A(12):2731-8. DOI: 10.1002/ajmg.a.33122. View

4.
Rowe H, Fisher J, Quinlivan J . Are pregnant Australian women well informed about prenatal genetic screening? A systematic investigation using the Multidimensional Measure of Informed Choice. Aust N Z J Obstet Gynaecol. 2006; 46(5):433-9. DOI: 10.1111/j.1479-828X.2006.00630.x. View

5.
Pieretti M, Zhang F, Fu Y, Warren S, Oostra B, Caskey C . Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991; 66(4):817-22. DOI: 10.1016/0092-8674(91)90125-i. View